Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies.

Khodoun MV, Morris SC, Angerman E, Potter C, Schuman R, Wunderlich M, Maciag JJ, Sullivan Locker KC, Mulloy JC, Herr AB, Finkelman FD.

J Allergy Clin Immunol. 2019 Dec 11. pii: S0091-6749(19)31632-X. doi: 10.1016/j.jaci.2019.12.003. [Epub ahead of print]

PMID:
31836406
2.

Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL.

Rodriguez S, Abundis C, Boccalatte F, Mehrotra P, Chiang MY, Yui MA, Wang L, Zhang H, Zollman A, Bonfim-Silva R, Kloetgen A, Palmer J, Sandusky G, Wunderlich M, Kaplan MH, Mulloy JC, Marcucci G, Aifantis I, Cardoso AA, Carlesso N.

Leukemia. 2019 Nov 26. doi: 10.1038/s41375-019-0653-z. [Epub ahead of print]

PMID:
31772299
3.

Improved chemotherapy modeling with RAG-based immune deficient mice.

Wunderlich M, Manning N, Sexton C, Sabulski A, Byerly L, O'Brien E, Perentesis JP, Mizukawa B, Mulloy JC.

PLoS One. 2019 Nov 20;14(11):e0225532. doi: 10.1371/journal.pone.0225532. eCollection 2019.

4.

Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt SB, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas CJ, Starczynowski DT.

Sci Transl Med. 2019 Sep 4;11(508). pii: eaaw8828. doi: 10.1126/scitranslmed.aaw8828.

PMID:
31484791
5.

Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.

Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, Ni T, Zhang ZS, Zhang T, Li C, Han L, Zhu Z, Lian F, Wei J, Deng Q, Wang Y, Wunderlich M, Gao Z, Pan G, Zhong D, Zhou H, Zhang N, Gan J, Jiang H, Mulloy JC, Qian Z, Chen J, Yang CG.

Cancer Cell. 2019 Apr 15;35(4):677-691.e10. doi: 10.1016/j.ccell.2019.03.006.

6.

Alternative translation initiation generates the N-terminal truncated form of RUNX1 that retains hematopoietic activity.

Goyama S, Schibler J, Mulloy JC.

Exp Hematol. 2019 Apr;72:27-35. doi: 10.1016/j.exphem.2019.01.008. Epub 2019 Jan 26.

PMID:
30690039
7.

Improved multilineage human hematopoietic reconstitution and function in NSGS mice.

Wunderlich M, Chou FS, Sexton C, Presicce P, Chougnet CA, Aliberti J, Mulloy JC.

PLoS One. 2018 Dec 12;13(12):e0209034. doi: 10.1371/journal.pone.0209034. eCollection 2018.

8.

Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.

Barve A, Casson L, Krem M, Wunderlich M, Mulloy JC, Beverly LJ.

Exp Hematol. 2018 Nov;67:18-31. doi: 10.1016/j.exphem.2018.08.004. Epub 2018 Aug 17.

9.

Cell Polarity and Division Symmetry Analyses in Transformed Blood Cells.

Mizukawa B, O'Brien E, Mulloy JC, Zheng Y.

Methods Mol Biol. 2018;1821:257-266. doi: 10.1007/978-1-4939-8612-5_18.

10.

Publisher Correction: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJM, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J.

Nat Commun. 2018 Apr 10;9:16192. doi: 10.1038/ncomms16192.

11.

Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.

Jiang X, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J.

Nat Commun. 2018 Feb 9;9(1):670. doi: 10.1038/s41467-018-02947-0.

12.

Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells.

Eriksson M, Peña-Martínez P, Ramakrishnan R, Chapellier M, Högberg C, Glowacki G, Orsmark-Pietras C, Velasco-Hernández T, Lazarević VL, Juliusson G, Cammenga J, Mulloy JC, Richter J, Fioretos T, Ebert BL, Järås M.

Blood Adv. 2017 Oct 18;1(23):2046-2057. doi: 10.1182/bloodadvances.2017006148. eCollection 2017 Oct 24.

13.

METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification.

Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore LC, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M, He C, Chen J.

Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9. doi: 10.1016/j.stem.2017.11.016. Epub 2017 Dec 28.

14.

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling.

Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki AT, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen J.

Cell. 2018 Jan 11;172(1-2):90-105.e23. doi: 10.1016/j.cell.2017.11.031. Epub 2017 Dec 14.

15.

Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.

Jiang X, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J.

Nat Commun. 2017 Dec 13;8(1):2099. doi: 10.1038/s41467-017-02290-w. Erratum in: Nat Commun. 2018 Feb 9;9(1):670.

16.

The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.

Mizukawa B, O'Brien E, Moreira DC, Wunderlich M, Hochstetler CL, Duan X, Liu W, Orr E, Grimes HL, Mulloy JC, Zheng Y.

Blood. 2017 Sep 14;130(11):1336-1346. doi: 10.1182/blood-2016-12-758458. Epub 2017 Aug 4.

17.

A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.

Lin S, Ptasinska A, Chen X, Shrestha M, Assi SA, Chin PS, Imperato MR, Aronow BJ, Zhang J, Weirauch MT, Bonifer C, Mulloy JC.

Blood. 2017 Sep 7;130(10):1213-1222. doi: 10.1182/blood-2016-11-750976. Epub 2017 Jul 14.

18.

The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.

Lin S, Luo RT, Shrestha M, Thirman MJ, Mulloy JC.

Blood. 2017 Aug 17;130(7):903-907. doi: 10.1182/blood-2017-04-777185. Epub 2017 Jun 21.

19.

CD44 variant isoform 9 emerges in response to injury and contributes to the regeneration of the gastric epithelium.

Bertaux-Skeirik N, Wunderlich M, Teal E, Chakrabarti J, Biesiada J, Mahe M, Sundaram N, Gabre J, Hawkins J, Jian G, Engevik AC, Yang L, Wang J, Goldenring JR, Qualls JE, Medvedovic M, Helmrath MA, Diwan T, Mulloy JC, Zavros Y.

J Pathol. 2017 Aug;242(4):463-475. doi: 10.1002/path.4918.

20.

Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.

Kesarwani M, Kincaid Z, Gomaa A, Huber E, Rohrabaugh S, Siddiqui Z, Bouso MF, Latif T, Xu M, Komurov K, Mulloy JC, Cancelas JA, Grimes HL, Azam M.

Nat Med. 2017 Apr;23(4):472-482. doi: 10.1038/nm.4310. Epub 2017 Mar 20.

Supplemental Content

Loading ...
Support Center